Skip to main content
Figure 3 | Molecular Cancer

Figure 3

From: Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non–small-cell lung cancer xenograft models

Figure 3

Effect of motesanib in combination with cisplatin on various NSCLC xenograft tumor models. Tumor volume (top) and body weight (bottom) over time in response to motesanib plus cisplatin. (A) Calu-6 tumors treated with vehicle, motesanib 75 mg/kg BID, cisplatin 5 mg/kg QW, or motesanib plus cisplatin at the same dose and schedule for 14 days. *P < 0.0001 for all groups vs vehicle; †P ≤ 0.05 for combination vs either single agent alone. (B) NCI-H358 tumors treated with vehicle, motesanib 15 mg/kg BID, cisplatin 5 mg/kg QW, or motesanib plus cisplatin at the same dose and schedule for 22 days. ‡P ≤ 0.001 for combination vs either single agent alone; P < 0.0001 for combination vs vehicle. (C) NCI-H1650 tumors treated with vehicle, motesanib 15 mg/kg QD, cisplatin 4 mg/kg QW, or motesanib plus cisplatin at the same dose and schedule for 21 days. §P = 0.001 for combination vs either single agent alone; P < 0.0001 for combination vs vehicle. #P < 0.0001 for combination vs vehicle, motesanib, or cisplatin alone. Data are expressed as mean ± SE.

Back to article page

Molecular Cancer

ISSN: 1476-4598